---
title: "Psilocybin (COMP360) in Treatment-resistant depression: Economic burden and healthcare resource utilization"
description: "Formulary evidence on Psilocybin (COMP360) in Treatment-resistant depression: Economic burden and healthcare resource utilization. Topics: National annual burden of TRD within medication-treated MDD in the United States; Incremental societal economic burden of MDD in the United States in 2019; Commercially insured adults: health care costs, work loss, and employment status change; Commercially insured adults with physical conditions: resource use, health care costs, and work loss; 12 further topics. 16 evidence topics quoted from 16 sources."
canonical: "https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description/economic-burden-and-healthcare-resource-utilization"
published: "2026-11-18T10:42:20-05:00"
modified: "2026-11-18T10:42:20-05:00"
---

# Psilocybin (COMP360) in Treatment-resistant depression: Economic burden and healthcare resource utilization

<a id="heading-2.2.1.8.2"></a>

## 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

### National annual burden of TRD within medication-treated MDD in the United States

> “The estimated 12-month prevalence of medication-treated MDD in the United States was 8.9 million adults, and 2.8 million (30.9%) had TRD.”
> “The total annual burden of medication-treated MDD among the US population was $92.7 billion, with $43.8 billion (47.2%) attributable to TRD.”
> “The share of TRD was 56.6% ($25.8 billion) of the health care burden, 47.7% ($8.7 billion) of the unemployment burden, and 32.2% ($9.3 billion) of the productivity burden of medication-treated MDD.”

Source: [Zhdanava et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33989464/)

<a id="topic-2.2.1.8.2-2"></a>

### Incremental societal economic burden of MDD in the United States in 2019

> “In 2019, the number of adults with MDD in the USA was estimated at 19.8 million (62.7% female; 32.9% severe MDD), and the incremental societal economic burden of MDD was estimated at $333.7 billion ($382.4 billion in 2023 US dollars), or $16,854 per adult with MDD.”
> “The primary cost drivers were healthcare costs ($127.3 billion; 38.1%), household-related costs ($80.1 billion; 24.0%), presenteeism ($43.3 billion; 13.0%), and absenteeism ($38.4 billion; 11.5%).”
> “In the simulated scenario, a hypothetical novel therapy with a 50.0% early response rate was associated with a 7.7% reduction in the economic burden of MDD relative to standard of care over 12 months.”

Source: [Greenberg et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10499687/)

<a id="topic-2.2.1.8.2-3"></a>

### Commercially insured adults: health care costs, work loss, and employment status change

> “TRD patients (N = 6,411) had more HRU than either matched control cohort, translating into higher per patient per year (PPPY) health care costs: $6,709 and $9,917 more than non-TRD MDD and non-MDD patients, respectively (P < .001 for both).”
> “TRD patients with work loss data (N = 1,908) had 35.8 work loss days PPPY (1.7 and 6.2 times the work loss rate in non-TRD MDD and non-MDD patients, respectively).”
> “Work loss-related costs in TRD patients were $1,811 higher than non-TRD MDD and $3,460 higher than in non-MDD patients (P < .001).”
> “TRD patients had 1.3-1.4 times the rate of employment status change versus control cohorts (all P < .05).”

Source: [Amos et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29474009/)

<a id="topic-2.2.1.8.2-4"></a>

### Commercially insured adults with physical conditions: resource use, health care costs, and work loss

> “A total of 2,317 patients with TRD (mean age, 47.6 years; 63.1%, female; mean follow-up, 19.7 months) had ≥ 1 co-occurring key physical condition (cardiovascular, 52.5%; metabolic, 48.2%; respiratory, 16.4%; and cancer, 9.5%).”
> “Relative to non-TRD MDD and non-MDD cohorts, respectively, patients with TRD had 46% and 235% more inpatient admissions, 28% and 128% more emergency department visits, and 53% and 155% more outpatient visits (all P < 0.05).”
> “Health care costs were $22,541 in the TRD cohort, $17,450 in the non-TRD MDD cohort, and $10,047 in the non-MDD cohort, yielding cost differences of $5,091 (vs. non-TRD MDD) and $12,494 (vs. non-MDD; all P < 0.01).”
> “In patients with work loss data available (n = 278/cohort), those with TRD had 2.0 and 2.9 times more work loss as well as $8,676 and $10,323 higher work loss costs relative to those with non-TRD MDD and without MDD, respectively (all P < 0.001).”

Source: [Zhdanava et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10391320/)

<a id="topic-2.2.1.8.2-5"></a>

### Commercially insured employees: direct and indirect costs over 2 years

> “Employees who initiated a third antidepressant following two antidepressant treatments of adequate dose and duration or who met published TRD criteria were classified as TRD likely (N = 2312).”
> “Average direct 2-year costs were significantly higher for TRD-likely employees ($22,784) compared with MDD controls ($11,733), p < 0.0001.”
> “Average indirect costs were also higher among TRD-likely employees ($12,765) compared with MDD controls ($6885), p < 0.0001.”

Source: [Ivanova et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20825269/)

<a id="topic-2.2.1.8.2-6"></a>

### Commercially insured adults: episode duration and total costs of TRD episodes

> “Of all episodes, 7% were TRD, with a mean duration of 571 (285) days vs. 200 (198) days for non-TRD MDD episodes.”
> “Mean total all-cause costs were $19,626 ($44,160) for TRD and $7440 ($25,150) for non-TRD MDD episodes.”

Source: [Cai et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31540559/)

<a id="topic-2.2.1.8.2-7"></a>

### Medicare beneficiaries: resource use and health care costs

> “Of these, 3,224 (10.9%) met the study definition of TRD.”
> “During the observation period, the total all-cause PPPY healthcare costs were $25,059 in the TRD cohort, $19,945 in the non-TRD MDD cohort, and $14,410 in the non-MDD cohort (all P<0.001; Fig 3 and Table 2).”
> “The TRD cohort had significantly higher adjusted PPPY all-cause healthcare costs versus the non-TRD MDD (adjusted cost difference = $3,377, P<0.001) or non-MDD cohorts (adjusted cost difference = $3,675, P<0.001; Fig 3 and Table 2).”
> “The TRD cohort had higher rates of PPPY behavioral health-related HRU relative to the non-TRD MDD cohort (e.g., inpatient visits: IRR = 1.49) and versus the non-MDD cohort (e.g., inpatient visits: IRR = 3.84, all P<0.001).”

Source: [Pilon et al. (2019b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6786597/)

<a id="topic-2.2.1.8.2-8"></a>

### Medicare beneficiaries: published correction of the abstract results

> “In the Results subsection of the Abstract. there are numbers reported which are inconsistent with those of the main text.”
> “The TRD cohort had significantly higher total PPPY healthcare costs than the non-TRD MDD cohort ($25,059 vs. $19,945, adjusted cost difference = $3,377) and non-MDD cohort ($25,059 vs. $14,410, adjusted cost difference = $3,675, all P<0.001).”

Source: [Pilon et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8016289/)

<a id="topic-2.2.1.8.2-9"></a>

### Medicare beneficiaries aged 65 years or older: resource use, costs, and hospitalization risk

> “After matching, 178 patients from each cohort were analyzed.”
> “During 12 months of follow-up, TRD patients had higher use of different antidepressants and antipsychotics, higher inpatient and emergency room visits, longer inpatient stays, and higher total healthcare costs ($24,543 versus $16,059, $8,058) than non-TRD MDD and non-MDD cohorts, respectively (all p <0.05).”
> “Risk of initial hospitalization was higher in the TRD (hazard ratio [HR] = 3.60, 95% confidence interval [CI] = 2.08-6.23) and non-TRD MDD cohorts (HR = 1.82, 95% CI = 1.02-3.25) than the non-MDD cohort.”

Source: [Benson et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31735488/)

<a id="topic-2.2.1.8.2-10"></a>

### Medicaid beneficiaries: resource use and costs

> “TRD beneficiaries had higher HRU than 1:1 matched non-TRD-MDD (e.g., inpatient visits: IRR = 1.41) and non-MDD beneficiaries (N = 14,710 per cohort; e.g., inpatient visits: IRR = 3.42, p < 0.01).”
> “TRD beneficiaries incurred greater costs versus non-TRD-MDD (CD = US$4382) and non-MDD beneficiaries (CD = US$8294; p < 0.05).”

Source: [Pilon et al. (2019a)](https://pubmed.ncbi.nlm.nih.gov/30734581/)

<a id="topic-2.2.1.8.2-11"></a>

### Medicaid beneficiaries initiating esketamine, electroconvulsive therapy, or transcranial magnetic stimulation: mental health-related resource use and costs

> “ESK cohort included 151 patients (mean age: 40.6 years; female: 70.2%), ECT cohort included 198 patients (mean age: 43.0 years; female: 60.6%), and TMS cohort included 140 patients (mean age: 39.5 years; female: 65.0%).”
> “Mean MH-related acute care costs during the follow-up period trended lower in ESK cohort (IP: $76; ED: $29) relative to ECT (IP: $1,547; ED: $45) and TMS cohorts (IP: $238; ED: $123).”
> “Outpatient costs in ESK cohort ($1,632) exceeded OP costs in ECT ($1,023) and TMS ($1,051) cohorts.”
> “This finding should be interpreted with caution, given potential differences in patient profiles, clinical history and setting of administration.”

Source: [Clemens et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/43010363/)

<a id="topic-2.2.1.8.2-12"></a>

### Veterans Health Administration: resource use and health care costs

> “After 1:1 exact matching, 10,449 patients were included in each cohort (mean age: 48.9 years).”
> “Patients with TRD had higher per patient per year (PPPY) HRU than non-TRD MDD (all-cause inpatient visits: incidence rate ratio [IRR]: 1.70 [95% confidence interval: 1.57-1.83]) and non-MDD (IRR: 5.04 [95% confidence interval: 4.51-5.63]), and incurred higher total all-cause health care costs PPPY than non-TRD MDD (mean difference: $5,906) and non-MDD (mean difference: $11,873; all p<.0001).”

Source: [Szukis et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33879005/)

<a id="topic-2.2.1.8.2-13"></a>

### Incremental health care and productivity costs across studies: systematic review of United States data, 1996 to 2013

> “Annual costs for health care and lost productivity were $5,481 and $4,048 higher, respectively, for patients with treatment-resistant versus treatment-responsive depression.”
> “At current rates of 12%-20% among all depressed patients, treatment-resistant depression may present an annual added societal cost of $29-$48 billion, pushing up the total societal costs of major depression by as much as $106-$118 billion.”

Source: [Mrazek et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24789696/)

<a id="topic-2.2.1.8.2-14"></a>

### Costs across increasing levels of non-response: systematic review

> “The 12 studies on economic burden found an association between increasing levels of TRD/non-response and elevations in direct and indirect costs.”

Source: [Johnston et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30195173/)

<a id="topic-2.2.1.8.2-15"></a>

### Inpatient bed-days, outpatient visits, and lost workdays: population-based cohort in Stockholm, Sweden

> “Of these, 12 793 episodes (11%) fulfilled criteria for TRD.”
> “Compared with matched non-TRD episodes, TRD episodes had more inpatient bed-days (mean, 3.9 days; 95% CI, 3.6-4.1, vs 1.3 days; 95% CI, 1.2-1.4) and more lost workdays (mean, 132.3 days; 95% CI, 129.5-135.1, vs 58.7 days; 95% CI, 56.8-60.6) 12 months after the index date.”
> “This cohort study found that, compared with patients with MDD and no TRD episodes, patients with TRD episodes had higher prevalence of psychiatric comorbid conditions, twice the utilization of outpatient health care resources, 3 times the number of inpatient bed-days, and 23% higher all-cause mortality.”

Source: [Lundberg et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9856735/)

<a id="topic-2.2.1.8.2-16"></a>

### Health care professional visits versus the general population: five European countries

> “Additionally, healthcare resource utilization was significantly higher for TRD patients more so than nTRD, compared to the general population, especially for healthcare professional visits (odds ratio nTRD = 5.4; TRD = 15.9, p < 0.001).”

Source: [Jaffe et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6686569/)

## Related pages
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Terms and abbreviations](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations.md)
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Product information and disease description](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Clinical evidence](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Economic information and modeling report](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: References](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references.md)
